Preparation method of sodium gualenate tablet with stable storage and long-acting release

By forming a polylactic acid and metal-organic framework composite coating on the surface of sodium azulene sulfonate tablets, the degradation problem of sodium azulene sulfonate tablets under light, air oxidation and high temperature conditions is solved, achieving drug stability and sustained-release effect, and ensuring the consistency of drug stability and therapeutic effect.

CN119015243APending Publication Date: 2024-11-26SHANDONG HUASU PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411159991.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Sodium azulene sulfonate tablets are easily degraded under light, air oxidation, and high temperature conditions. Existing technologies lack effective protective measures, resulting in insufficient drug stability and release control.

Method used

A polylactic acid and metal-organic framework composite coating is formed on the surface of sodium azulene sulfonate tablets. Specific pretreatment and posttreatment steps ensure uniform adhesion of the coating. The pore structure of MOF and the biodegradability of PLA are used to achieve drug stability and sustained release.

Benefits of technology

This improved the storage stability of sodium azulene sulfonate tablets, enabling sustained and controlled release of the drug and ensuring consistent drug release characteristics and therapeutic efficacy under various conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005006156220000121
    Figure BDA0005006156220000121
  • Figure BDA0005006156220000131
    Figure BDA0005006156220000131
  • Figure BDA0005006156220000141
    Figure BDA0005006156220000141
Patent Text Reader

Abstract

According to the preparation method of the sodium gualenate tablet with stable storage and long-acting release, the polylactic acid and metal organic framework composite coating is formed on the surface of the sodium gualenate tablet, so that the stability of the medicine is effectively improved, the release of the medicine is controlled, uniform adhesion of the coating is ensured by utilizing a specific pretreatment step, and the storage stability and the long-acting release of the sodium gualenate tablet are improved. A uniform and stable metal organic framework (MOF) coating and a uniform and stable polylactic acid (PLA) coating are formed by adopting a dip-coating method, and the stability and adhesive force of the coatings are enhanced through a post-treatment step, so that the overall performance of the tablet is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical preparations, and in particular to a sodium azulene sulfonate tablet capable of improving storage stability and long-acting release, and a preparation method thereof. Background Art

[0002] As a compound widely used in the medical field, sodium azulene sulfonate has been widely recognized for its anti-inflammatory, antioxidant and wound healing effects. However, the sulfonic acid group (-SO3H) in the sodium azulene sulfonate molecule is prone to photolysis or thermal decomposition under light and high temperature, resulting in the detachment of the sulfonic acid group or the formation of other by-products. In addition, the conjugated double bond system in the molecule is prone to π-π* electron transition under light, causing photooxidation reaction, thereby destroying the stability of the molecule. Under air oxidation conditions, these double bonds are also easily oxidized to form peroxides or other oxidation products, which not only reduces the active ingredients of the drug, but also affects the safety and effectiveness of the drug. During daily storage, especially under light, air oxidation and high temperature conditions, if it is not protected, it is easy to lead to reduced efficacy, limiting its possibility of long-term storage and application.

[0003] Currently, sodium azulene sulfonate tablets on the market mostly adopt simple packaging or direct compression molding, lacking effective protective measures, which not only affects the stability of the drug, but also limits the controllability of drug release. The prior art has obvious limitations in improving drug stability and controlling release rate. Although CN100425228C provides the use of specific disintegrants to achieve storage stability and drug release, it is obvious that the disintegrant itself does not have control and has a strong possibility of random disintegration, resulting in unsatisfactory effects in actual use. Summary of the invention

[0004] In order to solve the problems in the prior art, the present invention forms a polylactic acid and metal organic framework composite coating on the surface of sodium azulene sulfonate tablets, thereby effectively improving the stability of the drug and controlling the drug release. The present invention uses a specific pretreatment step to ensure uniform adhesion of the coating, uses a dip coating method to form a uniform and stable metal organic framework coating (MOF) and polylactic acid coating (PLA), and enhances the stability and adhesion of the coating through a post-treatment step, thereby improving the overall performance of the tablet.

[0005] The specific plan is as follows:

[0006] A method for preparing a sodium azulene sulfonate tablet coated with a composite coating, comprising the following steps:

[0007] a. Pretreatment of sodium azulene sulfonate tablets: The sodium azulene sulfonate tablets were washed with anhydrous ethanol and then dried in an oven at 40°C for at least 2 hours;

[0008] b. Formation of MOF coating:

[0009] b1: Dissolve Zn(NO3)2·6H2O and HmIm (2-methylimidazole) in N,N-dimethylformamide (DMF) in a stoichiometric ratio to form a uniform precursor solution;

[0010] b2: Dip the dried tablet into the MOF precursor solution and ensure complete coverage;

[0011] b3: Soak at room temperature for 0.5-8h to allow MOF crystals to grow on the tablet surface;

[0012] b4: The tablet was taken out, rinsed with DMF to remove unattached MOF particles, and then dried at 40 °C for 24 h;

[0013] c. Forming PLA coating:

[0014] Dissolve polylactic acid in chloroform to form a 2wt%-5wt% polylactic acid solution, wherein the weight average molecular weight of the polylactic acid is 10 5 -3×10 5 , immerse the tablet with MOF coating in step b into the polylactic acid solution, and ensure that it is completely covered, soak at room temperature for 5-30 minutes, and then dry at room temperature;

[0015] d. Post-curing treatment:

[0016] The mixed-coated sodium azulene sulfonate tablets obtained in step c are cured at 40-60° C. for 2-8 hours to obtain the final sodium azulene sulfonate tablets coated with the composite coating.

[0017] In one of the schemes, in step a, the sodium azulene sulfonate tablets are 0.2-0.6 g, but for the same batch of tablets, the mass deviation is less than 2%; the effective amount of sodium azulene sulfonate is 2 mg-50 mg; the remainder is filler, binder, disintegrant and lubricant.

[0018] Furthermore, in one of the schemes, in step a, the sodium azulene sulfonate tablet further comprises 5-20 wt % of L-glutamine based on the total mass of the tablet.

[0019] In one of the schemes, in step a, the washed sodium azulene sulfonate tablets are further immersed in a 2wt%-5wt% polyvinyl alcohol solution, wherein the solvent is chloroform, and after immersing at room temperature for 5-30 minutes, the tablets are dried at 40°C for 2-8 hours.

[0020] In one embodiment, in step b1, the stoichiometric ratio is a molar ratio of Zn(NO3)2·6H2O to HmIm of 1:1-1:2.

[0021] In one of the schemes, in step b1, the content of the precursor solution is 2wt%-10wt%.

[0022] In one embodiment, the water content of the final sodium azulene sulfonate tablet coated with the composite coating is below 0.3 wt %.

[0023] The present invention also protects the sodium azulene sulfonate tablets coated with a composite coating prepared by the preparation method of the present invention.

[0024] Beneficial effects:

[0025] The present invention effectively improves the stability of the drug and controls the drug release by forming a polylactic acid (PLA) and metal organic framework (MOF) composite coating on the surface of the sodium azulene sulfonate tablet. The design of this composite coating utilizes the unique pore structure and high specific surface area of ​​MOF, as well as the good biodegradability and biocompatibility of polylactic acid. The MOF coating not only provides a stable physical barrier for drug molecules, protects the drug from environmental factors such as humidity, light and oxygen, and reduces the degradation of the drug during storage and transportation, but also its pore structure can be used as a carrier of drug molecules to achieve sustained release and controlled release of the drug. The polylactic acid coating further enhances the sustained release effect of the drug, and due to its biodegradability, it can gradually degrade in the body to release the drug molecules, thereby achieving a more ideal drug efficacy and reducing side effects. In addition, the uniform adhesion and stability of the composite coating are further enhanced by specific pretreatment and post-treatment steps, ensuring that each sodium azulene sulfonate tablet can maintain consistent drug release characteristics and therapeutic effects under various conditions. DETAILED DESCRIPTION

[0026] Although the present invention has been described to a certain extent, it is obvious that appropriate changes in various conditions can be made without departing from the spirit and scope of the present invention. It is understood that the present invention is not limited to the embodiments described, but belongs to the scope of the claims, which includes equivalent replacements of each factor described.

[0027] In step a of the present invention, an initial sodium azulene sulfonate tablet is selected for pretreatment. The initial sodium azulene sulfonate tablet is a pharmaceutical preparation containing 2 mg to 50 mg of effective sodium azulene sulfonate, and the molding and function of the tablet are ensured by adding fillers, binders, disintegrants and lubricants, preferably 5 mg to 40 mg, and more preferably 8 mg to 35 mg. In order to ensure the consistency and stability of the tablets, the quality deviation of the tablets in the same batch is controlled within 2%, preferably within 1.5%, and more preferably within 1%. In order to take into account the effective dose and the comfort of swallowing at the entrance, and to adapt to different medication needs, the mass range of the initial sodium azulene sulfonate tablet is 0.2-0.6g, preferably 0.3-0.5g.

[0028] The filler described in the present invention is used to increase the volume of the tablet and improve its formability. The filler selected in the present invention includes one or more of microcrystalline cellulose, lactose, mannitol, and starch, and the content accounts for 20wt% to 90wt% of the total mass of the tablet, preferably 30wt% to 85wt%, and more preferably 40wt% to 70wt%.

[0029] The binder described in the present invention is used to increase the adhesion between particles and the molding stability. The binder selected in the present invention includes one or more of sodium carboxymethyl cellulose, sodium alginate, hydroxypropyl cellulose (HPC), and polyvinyl pyrrolidone (PVP), and the content accounts for 1wt% to 5wt% of the total mass of the tablet, preferably 2wt% to 4wt%.

[0030] The disintegrant of the present invention is used to promote rapid decomposition of the tablet in the body, thereby releasing the drug. Some of the binders have the performance of disintegrants, such as sodium carboxymethyl cellulose. Other disintegrants selected by the present invention also include one or more of microcrystalline cellulose (MCC), low-substituted hydroxypropyl cellulose (L-HPC), and cross-linked polyvinylpyrrolidone. The content of the disintegrant accounts for 5wt% to 10wt% of the total mass of the tablet, preferably 6wt% to 8wt%.

[0031] The lubricant of the present invention is used to reduce the friction of the tablet during the compression process and improve the smoothness of the tablet. The lubricant selected by the present invention includes one or more of magnesium stearate, talc, and polyethylene glycol (PEG), and the content accounts for 0.5% to 3% of the total mass of the tablet, preferably 1wt% to 2wt%.

[0032] From the perspective of promoting the absorption of sodium azulene sulfonate tablets and increasing the anti-inflammatory effect of the drug, the sodium azulene sulfonate tablets also include 5wt%-20wt% of L-glutamine based on the total mass of the tablet, preferably 7wt%-15wt%. L-glutamine may help improve the health of intestinal cells, thereby promoting the absorption of the drug, while reducing the inflammatory response, synergizing with the anti-inflammatory effect of sodium azulene sulfonate, and enhancing the therapeutic effect.

[0033] During the pretreatment process, the sodium azulene sulfonate tablets are first washed with anhydrous ethanol to remove impurities, and then dried in an oven at 40°C for at least 2 hours, preferably 3-5 hours, to ensure that the surface is clean and free of moisture. From the perspective of increasing the adhesion of the coating, the tablets are preferably further treated with a polyvinyl alcohol solution after washing and before drying.

[0034] In the present invention, Metal-Organic Frameworks (MOF) as a new type of porous material with a unique pore structure and high specific surface area is used for the preparation of the surface coating of sodium azulene sulfonate tablets. Metal-organic frameworks are a type of porous crystalline material formed by self-assembly of metal ions or metal clusters and organic ligands. The pore structure of MOF can be regulated by selecting different metal ions and organic ligands, thereby achieving precise design of pore size, shape and chemical properties. In the present invention, the preparation of the MOF coating is that Zn(NO3)2·6H2O and HmIm (2-methylimidazole) are dissolved in N,N-dimethylformamide (DMF) according to a certain stoichiometric ratio to form a uniform precursor solution. This precursor solution is the basis for the growth of MOF crystals. Zinc salt and imidazole or its derivatives serve as organic ligands to form a porous structure with high thermal and chemical stability, and have good biocompatibility and biodegradability, so it is very suitable for oral sodium azulene sulfonate tablets. Compared with other MOF materials, such as HKUST-1 formed by copper ions and 1,3,5-benzenetricarboxylic acid or UiO-66 formed by zirconium ions and 1,4-benzenedicarboxylic acid, it has better storage stability and drug release of the active ingredient of sodium azulene sulfonate.

[0035] The molar ratio of Zn(NO3)2·6H2O to HmIm is 1:1 to 1:2, preferably 1:1.2 to 1:1.8, and further preferably 1.4 to 1.6. When within this molar ratio range, the growth rate and final structural properties of the MOF crystal can be affected, so that it can form an ideal pore structure, form a loading space for sodium azulene sulfonate, and have a stable structure that is not easy to collapse during the release of sodium azulene sulfonate.

[0036] The concentration of the precursor solution is between 2wt% and 10wt%, preferably 4wt% to 8wt%. The choice of the precursor concentration mainly affects the growth rate of the MOF crystal and the final pore structure. Experiments show that when the precursor concentration is in this range, the growth rate of the MOF crystal on the tablet surface is faster, usually no more than 8 hours to fully crystallize, can form an ideal pore structure, and remain stable, and is not easy to collapse during the release of sodium azulene sulfonate. Therefore, in order to cover as much MOF crystal as possible on the tablet surface, it is necessary to soak at room temperature for 0.5-8h, preferably 1-6h.

[0037] After taking out the tablets, rinse with DMF to remove the unattached MOF particles, and then dry at 40 ° C for 24 hours. During the MOF crystal growth process, some crystallized MOF particles may not be firmly attached to the tablet surface. Rinsing with DMF can effectively remove these unattached particles and prevent them from falling off during the drying process, thereby ensuring the uniformity and integrity of the coating. At the same time, DMF can also dissolve and remove byproducts or residues that may be generated during the MOF growth process, making the surface of the MOF layer clean and providing a clean surface for the subsequent formation of the PLA coating.

[0038] A polylactic acid coating is further coated on the outer layer of the MOF layer to achieve more precise drug release control through a double-layer controlled release mechanism. The MOF coating provides a porous structure to adsorb and store drug molecules, while the PLA coating serves as an outer controlled release layer. The combination of the two not only enhances the stability of sodium azulene sulfonate loaded on the carrier, but also achieves the timed and quantitative release of sodium azulene sulfonate through gradual degradation. By forming a polylactic acid (PLA) and metal organic framework (MOF) composite coating on the surface of sodium azulene sulfonate tablets, not only can the stability of the active ingredient of sodium azulene sulfonate be maintained during storage, but during the release of the active ingredient of sodium azulene sulfonate, PLA can be degraded synchronously to ensure a slightly acidic system during its release, and the slightly acidic system is relatively stable for sodium azulene sulfonate and is not prone to hydrolysis reaction, so that it can maintain chemical stability before the drug release reaches the inflammatory site, and can better resist inflammation.

[0039] Polylactic acid is dissolved in chloroform to form a 2wt%-5wt% polylactic acid solution, preferably 3wt% to 4wt%. This range of concentrations ensures that the polylactic acid is evenly dispersed in the solvent while providing sufficient solid content to form a continuous and stable coating. Too low a concentration may result in a coating that is too thin to provide the desired protection and sustained release effects, while too high a concentration may result in a coating that is too thick or uneven. The soaking time is 5-30min, preferably 10-20min, which determines the extent of adsorption and deposition of polylactic acid on the tablet surface. A shorter time may not be enough to form a uniform coating, while a longer time helps the uniformity and adhesion of the coating, but the time for solvent evaporation and coating curing may also need to be considered. Finally, drying at room temperature is the process of coating curing, allowing the solvent chloroform to evaporate naturally, while polylactic acid forms a solid film on the tablet surface. The weight average molecular weight of polylactic acid is 10 5 -3×10 5 , preferably 1.5×10 5 -2.5×10 5 Within this range, the viscosity of the polylactic acid solution is moderate, which is helpful to form a uniform coating, and the degradation rate is moderate, which is well matched with the release rate of sodium azulene sulfonate.

[0040] After forming two layers of coating respectively, the sodium azulene sulfonate tablets are cured at 40-60°C for 2-8h to obtain the final sodium azulene sulfonate tablets coated with the composite coating. Preferably, it is cured at 45-55°C for 3-7h, and more preferably at 48-52°C for 4-6h. Through this step, on the one hand, the bonding force between the MOF coating, the PLA coating and the initial sodium azulene sulfonate tablets is further enhanced to ensure that the coating is not easy to fall off or break during subsequent use. On the other hand, the solvent in the composite coating is volatilized as much as possible to reduce the water content of the tablets and improve the storage stability of sodium azulene sulfonate. Through the water content test, the volatilization of the solvent is evaluated, and the water content of the final sodium azulene sulfonate tablets coated with the composite coating is controlled to be below 0.3wt%, preferably below 0.2wt%, and further preferably below 0.1wt%.

[0041] Preparation of initial sodium azulene sulfonate tablets (homemade):

[0042] Take 2g of sodium azulene sulfonate, 85g of starch, and 8g of microcrystalline cellulose. Dry the starch first, pass it through a 120-mesh sieve, and then mix it with sodium azulene sulfonate and microcrystalline cellulose, pass it through a 120-mesh sieve twice, and then mix it with 3g of sodium carboxymethyl cellulose and 2g of polyethylene glycol, press it into sheets, and prepare 250 initial tablets of the present invention. The active ingredient of sodium azulene sulfonate in each tablet is 8mg. Except for Example 2, the remaining examples and comparative examples all use the homemade sodium azulene sulfonate initial tablets of the present invention.

[0043] Example 1 (Basic)

[0044] The sodium azulene sulfonate tablets were washed with anhydrous ethanol, then immersed in a 3wt% polyvinyl alcohol / chloroform solution for 10 minutes, and dried in an oven at 40°C for 3 hours; Zn(NO3)2·6H2O and HmIm (2-methylimidazole) were dissolved in N,N-dimethylformamide (DMF) at a molar ratio of 1:1.05 to form a 5wt% precursor solution; the dried sodium azulene sulfonate tablets were immersed in the precursor solution at room temperature and kept completely covered, and the immersion was maintained for 4 hours, then the tablets were taken out, rinsed with DMF to remove unattached MOF particles, and then dried at 40°C for 24 hours;

[0045] Polylactic acid was dissolved in chloroform to form a 3 wt % polylactic acid solution, wherein the weight average molecular weight of polylactic acid was 2×10 5 The tablets with MOF coating were immersed in the polylactic acid solution and ensured to be completely covered. After soaking at room temperature for 20 minutes, they were dried at room temperature; then cured at 50°C for 4 hours to obtain the final composite coating-coated sodium azulene sulfonate tablets.

[0046] Example 2 (addition of L-glutamine)

[0047] Example 2 The ingredients of the homemade sodium azulene sulfonate tablets in Example 1 were adjusted, wherein the starch was 70 g, and 15 g of L-glutamine was added, while the other components remained unchanged, and the preparation process of the composite coating coating also remained unchanged.

[0048] Example 3 Precursor liquid is too small

[0049] Compared with Example 1, other conditions remained unchanged, and the concentration of the prepared precursor solution was 2 wt %.

[0050] Example 4 Precursor fluid is too large

[0051] Compared with Example 1, other conditions remained unchanged, and the concentration of the prepared precursor solution was 10 wt %.

[0052] Example 5 Lactic acid molecular weight is too small

[0053] Compared with Example 1, other conditions remain unchanged, and the weight average molecular weight of polylactic acid is 1×10 5 .

[0054] Example 6 Lactic acid molecular weight is too large

[0055] Compared with Example 1, other conditions remain unchanged, and the weight average molecular weight of polylactic acid is 3×10 5 .

[0056] Example 7 Lactic acid content is too low

[0057] Compared with Example 1, other conditions remained unchanged and the concentration of the prepared polylactic acid solution was 2 wt %.

[0058] Example 8 Lactic acid content is too high

[0059] Compared with Example 1, other conditions remained unchanged and the concentration of the prepared polylactic acid solution was 5 wt %.

[0060] Example 9: Soaking time is short

[0061] Compared with Example 1, other conditions remained unchanged, the immersion time in the precursor solution was 0.5 h, and the immersion time in the polylactic acid solution was 5 min.

[0062] Example 10

[0063] Compared with Example 1, other conditions remained unchanged, the immersion time in the precursor solution was 8 hours, and the immersion time in the polylactic acid solution was 30 minutes.

[0064] Example 11 The curing time is too short

[0065] Compared with Example 1, other conditions remained unchanged, and after forming two layers of coating, the sodium azulene sulfonate tablets were cured at 40° C. for 2 h.

[0066] Example 12: The curing time is too long

[0067] Compared with Example 1, other conditions remained unchanged, and after forming two layers of coating, the sodium azulene sulfonate tablets were cured at 60° C. for 8 h.

[0068] Comparative Example 1: No Precursor

[0069] Compared with Example 1, other conditions remain unchanged, and there is no step of soaking in the Zn(NO3)2·6H2O and HmIm precursor solutions.

[0070] Comparative Example 2 without lactic acid

[0071] Compared with Example 1, other conditions remain unchanged, and there is no step of soaking in the polylactic acid solution.

[0072] Comparative Example 3 Lactic acid molecular weight is small

[0073] Compared with Example 1, other conditions remain unchanged, and the weight average molecular weight of polylactic acid is 5×10 4 .

[0074] Comparative Example 4 Lactic acid has a large molecular weight

[0075] Compared with Example 1, other conditions remain unchanged, and the weight average molecular weight of polylactic acid is 5×10 5 .

[0076] Comparative Example 5 Precursor content is small

[0077] Compared with Example 1, other conditions remained unchanged, and the concentration of the prepared precursor solution was 1.5 wt %.

[0078] Comparative Example 6 Precursor content is large

[0079] Compared with Example 1, other conditions remained unchanged, and the concentration of the prepared precursor solution was 12 wt %.

[0080] Comparative Example 7 Lactic acid content is small

[0081] Compared with Example 1, other conditions remained unchanged and the concentration of the prepared polylactic acid solution was 1.5 wt %.

[0082] Comparative Example 8 Lactic acid content is large

[0083] Compared with Example 1, other conditions remained unchanged and the concentration of the prepared polylactic acid solution was 6 wt %.

[0084] Comparative Example 9: Insufficient soaking time

[0085] Compared with Example 1, other conditions remained unchanged, the immersion time in the precursor solution was 0.3 h, and the immersion time in the polylactic acid solution was 3 min.

[0086] Comparative Example 10: Post-treatment curing temperature is not enough

[0087] Compared with Example 1, other conditions remained unchanged, and after forming two layers of coating, the sodium azulene sulfonate tablets were cured at 35° C. for 2 h.

[0088] Comparative Example 11: Post-treatment temperature is too high

[0089] Compared with Example 1, other conditions remained unchanged, and after forming two layers of coating, the sodium azulene sulfonate tablets were cured at 70° C. for 2 h.

[0090] Examples 1-12 and Comparative Examples 1-11 were subjected to accelerated stability tests under illumination test and accelerated stability tests under high temperature and high humidity test, respectively, and the release rate of the effective substance was determined by dissolution determination method.

[0091] Experimental Example 1:

[0092] The test method for the accelerated stability experiment under the light test is:

[0093] Following the test method of "9001 Guidelines for Stability Testing of Raw Materials and Preparations" of the 2020 edition of the Chinese Pharmacopoeia, the prepared sodium azulene sulfonate tablets were placed in a light box and dispersed. The light source was a cool white fluorescent lamp that met the D65 / ID65 emission standard. The illumination condition was 4500lx±500lx. The thickness of the tablets did not exceed 3mm. Samples were taken after 1 day, 5 days, 10 days, and 30 days, and the effective amount of sodium azulene sulfonate was determined. The test results are shown in Table 1.

[0094] The effective amount test method of sodium azulene sulfonate is:

[0095] Determination of the content of sodium azulene sulfonate: octadecyl silane silica gel is used as a filler; acetonitrile-0.01 mol / L sodium acetate (containing 0.01 mol / L benzyltriethylammonium chloride) (4:6) is used as a mobile phase; and the detection wavelength is 293 nm. Take the samples of Examples 1-12 and Comparative Examples 1-11 that have undergone stability test experiments, accurately weigh, grind, accurately weigh 0.4 g (approximately equivalent to 8 mg of sodium azulene sulfonate), place in a 25 ml volumetric flask, add an appropriate amount of mobile phase and shake, dilute to the scale, shake thoroughly for 30 minutes, centrifuge (3000 rpm) for 10 minutes, accurately measure 5 ml of the supernatant, place in a 25 ml volumetric flask, add the mobile phase and dilute to the scale, shake well, as the test solution, accurately measure 20 μl and inject into the high performance liquid chromatograph, and measure the peak area; take another 8 mg of sodium azulene sulfonate, add the mobile phase to prepare a solution of the same concentration as the reference solution, and determine it in the same way as the test solution, and calculate the peak area by the external standard method.

[0096] Table 1: Accelerated stability test under light conditions

[0097]

[0098] It can be seen from the table that although Examples 1-12 have been adjusted in terms of component raw materials, precursor content, polylactic acid content and molecular weight, immersion time, curing time and temperature, the overall stability under specific light is good, and after 30 days, the effective content of the sodium azulene sulfonate tablets can still be maintained at more than 89.5% compared to the initial sodium azulene sulfonate tablets. When the polylactic acid coating and the MOFs coating are missing or the content, molecular weight, immersion time, and curing time are not within the range, the stability decreases faster, and if the curing temperature is 70°C, the higher curing temperature will cause the stability of the sodium azulene sulfonate tablets to deteriorate.

[0099] Experimental Example 2:

[0100] The test method for the accelerated stability experiment under high temperature and high humidity test is:

[0101] Also following the test method of the "9001 Guidelines for Stability Testing of Active Pharmaceutical Ingredients and Preparations" of the 2020 edition of the Chinese Pharmacopoeia, the prepared sodium azulene sulfonate tablets were placed with their openings in a constant humidity closed container and dispersed. The tablets were not larger than 3 mm, and the temperature of the constant humidity closed container was controlled to 55°C, and the relative humidity was 90%±5%. The light source was a cool white fluorescent lamp that met the D65 / ID65 emission standard, and the illumination condition was 4500lx±500lx. Samples were taken after 1 day, 5 days, 10 days, and 30 days, respectively. After drying at room temperature, the effective amount of sodium azulene sulfonate was determined. The test results are shown in Table 2.

[0102] The testing method of the effective amount of sodium azulene sulfonate is the same as that in Experimental Example 1.

[0103] Table 2: Accelerated stability test under high temperature and high humidity test conditions

[0104]

[0105] As can be seen from Table 2, the results are similar to those in Table 1. Although Examples 1-12 have been adjusted in terms of component raw materials, precursor content, polylactic acid content and molecular weight, immersion time, curing time and temperature, the overall stability under specific illumination is good, and after 30 days, the effective content of the sodium azulene sulfonate tablets can still be maintained at more than 89.5% compared to the initial azulene sulfonate tablets. When the polylactic acid coating and the MOFs coating are missing or the content, molecular weight, immersion time, and curing time are not within the range, the stability decreases faster, and if the curing temperature is 70°C, the higher curing temperature will also cause the stability of the sodium azulene sulfonate tablets to deteriorate.

[0106] Experimental Example 3:

[0107] Dissolution test method for testing the release of effective substances:

[0108] According to the dissolution method (Appendix XC Method 2 of Part II of the Chinese Pharmacopoeia 2010 Edition), take the samples prepared in Examples 1-12 and Comparative Examples 1-11, use 900 ml of water as the dissolution medium, the temperature is 25°C, the speed is 50 revolutions per minute, operate according to the law, take an appropriate amount of the solution and filter it at 2, 4, 8, 12, and 24 hours, and add water at the same temperature to the operating container in time, and use the filtrate as the test solution; accurately weigh 0.8 g of the sodium azulene sulfonate reference substance that had been dried overnight on silica gel, put it in a 100 ml volumetric flask, add water to dissolve and dilute to the scale, shake well, accurately measure 1 ml, put it in a 100 ml volumetric flask, add water to dissolve and dilute to the scale, shake well, as the reference solution. The above solutions were taken for measurement of absorbance at a wavelength of 293 nm according to the UV-Vis spectrophotometry (Appendix IVA of Part II of the Chinese Pharmacopoeia 2010 edition), and the release rate was calculated according to the external standard method. The test results are shown in Table 3.

[0109] Table 3 Dissolution test results of effective substance release

[0110]

[0111]

[0112] As can be seen from Table 3, although Examples 1-12 have been adjusted in terms of component raw materials, precursor content, polylactic acid content and molecular weight, soaking time, curing time and temperature, the release amount shows a trend of gradual release at 2, 4, 8, 12, and 24 hours, and complete release is achieved at 24 hours, and the release amount is above 96%, that is, a sustained release effect with obvious control in a simulated environment. When the polylactic acid coating and the MOFs coating are missing or the content, molecular weight, soaking time, and curing time are not within the range, some comparative examples (Comparative Examples 1 / 2 / 5 / 7 / 9) show a large release amount in the early stage, which has tended to balance after 8 hours; other comparative examples (Comparative Examples 6 / 11) reflect the situation that the effective release amount is insufficient and the drug conversion rate is not ideal.

[0113] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit it. Although the present application has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present application.

Claims

1. A method for preparing a sodium azulene sulfonate tablet coated with a composite coating, It is characterized in that The steps include: a. Pretreatment of sodium azulene sulfonate tablets: The sodium azulene sulfonate tablets were washed with anhydrous ethanol and then dried in an oven at 40°C for at least 2 hours; b. Formation of metal organic framework coating: b1: Zn(NO 3 ) 2 6H 2 O and 2-methylimidazole were dissolved in N,N-dimethylformamide in a stoichiometric ratio to form a uniform precursor solution; b2: Dip the dried tablet into the MOF coating precursor solution and ensure complete coverage; b3: Soak at room temperature for 0.5-8h to allow the metal organic framework coating crystals to grow on the tablet surface; b4: The tablets were taken out and rinsed with N,N-dimethylformamide to remove the unattached metal organic framework coating particles, and then dried at 40 °C for 24 h; c. Formation of polylactic acid coating: Dissolve polylactic acid in chloroform to form a 2wt%-5wt% polylactic acid solution, wherein the weight average molecular weight of the polylactic acid is 10 5 Up to 3×10 5 , immersing the tablet with the metal organic framework coating in step b into the polylactic acid solution, ensuring that it is completely covered, soaking at room temperature for 5-30 minutes, and then drying at room temperature; d. Post-curing treatment: The mixed-coated sodium azulene sulfonate tablets obtained in step c are cured at 40-60° C. for 2-8 hours to obtain the final sodium azulene sulfonate tablets coated with the composite coating.

2. The preparation method according to claim 1, It is characterized in that In step a, the sodium azulene sulfonate tablets are 0.2-0.6 g, and for the same batch of tablets, the mass deviation is less than 2%; The effective amount of sodium azulene sulfonate is 2mg-50mg; The balance is fillers, binders, disintegrants and lubricants.

3. The preparation method according to claim 1, It is characterized in that In step a, the sodium azulene sulfonate tablet further comprises 5-20 wt % of L-glutamine based on the total mass of the tablet.

4. The preparation method according to claim 1, It is characterized in that In step a, the washed sodium azulene sulfonate tablets are immersed in a 2wt%-5wt% polyvinyl alcohol solution, wherein the solvent is chloroform, and the solution is immersed at room temperature for 5-30 minutes, and then dried at 40°C for 2-8 hours.

5. The preparation method according to claim 1, It is characterized in that In step b1, the stoichiometric ratio is Zn(NO 3 ) 2 6H 2 The molar ratio of O and 2-methylimidazole is 1:1-1:

2.

6. The preparation method according to claim 1, It is characterized in that In step b1, the content of the precursor solution is 2wt%-10wt%.

7. The preparation method according to claim 1, It is characterized in that The water content of the final sodium azulene sulfonate tablets coated with the composite coating is below 0.3wt%.

8. A sodium azulene sulfonate tablet coated with a composite coating prepared according to the preparation method of any one of claims 1 to 7.